Erratum to: Increased serum potassium affects renal outcomes: a post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial

類似資料

• Increased serum potassium affects renal outcomes: a post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial
  著者:: Miao, Y., 等
  出版事項: (2010)
• Losartan and end‐organ protection—lessons from the renaal study
  著者:: Kowey, Peter R., 等
  出版事項: (2006)
• High serum potassium levels after losartan can reflect more severe renal disease. Reply to Gonçalves AR, El Nahas AM [letter]
  著者:: Roscioni, S. S., 等
  出版事項: (2011)
• Losartan and diabetic nephropathy: commentaries on the RENAAL study
  著者:: Fisman, Enrique Z, 等
  出版事項: (2002)
• Initial Angiotensin Receptor Blockade–Induced Decrease in Albuminuria Is Associated With Long-Term Renal Outcome in Type 2 Diabetic Patients With Microalbuminuria: A post hoc analysis of the IRMA-2 trial
  著者:: Hellemons, Merel E., 等
  出版事項: (2011)